EyePoint Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

EyePoint

05/03/2025 18:34

EyePoint Pharmaceuticals Inc EYPT.OQ reported a quarterly adjusted loss of 64 cents​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of -33 cents.  The mean expectation of thirteen analysts for the quarter was for a loss of 50 cents per share. Wall Street expected results to range from -64 cents to -31 cents per share.

Revenue fell 17.4% to $11.59 million from a year ago; analysts expected $11.09 million.

EyePoint Pharmaceuticals Inc's reported EPS for the quarter was a loss of 64 cents​.

The company reported a quarterly loss of $41.4 million.

EyePoint Pharmaceuticals Inc shares had fallen by 18.4% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 4.5% in the last three months.​

In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for EyePoint Pharmaceuticals Inc is $31.50

This summary was machine generated from LSEG data March 5 at 06:34 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
-0.50
-0.64
Missed
Sep. 30 2024
-0.56
-0.54
Beat
Jun. 30 2024
-0.52
-0.58
Missed
Mar. 31 2024
-0.42
-0.55
Missed